Most Read Articles
20 hours ago
In advanced-stage, newly diagnosed classical, CD30-positive Hodgkin lymphoma (HL), front-line therapy has resulted in durable remission rates in up to 70–90% of patients, although approximately 25–30% of advanced stage HL patients are refractory or relapse following first-line treatment with ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) chemotherapy.1–3 The standard of care for patients with relapsed or refractory (r/r) classical HL is salvage therapy using second-line high-dose chemotherapy (HDCT), followed by autologous haematopoietic stem cell transplant (ASCT) in eligible patients, which can induce a complete remission (CR) in about 50% of patients.4 Nevertheless, the prognosis of patients who relapse after the salvage HDCT/ASCT is exceedingly poor, with a median survival duration of approximately 1.2 years.5
22 Jan 2018
In a symposium chaired by Dr Yoon-Sim Yap of the National Cancer Centre Singapore, renowned regional and international experts in the field of breast cancer, Dr Yen-Shen Lu from Taiwan and Professor Nadia Harbeck from Germany, joined her in providing insights on the current treatment landscape of hormone receptor-positive (HR+) advanced breast cancer. In their respective sessions, they each highlighted new therapeutic options including the optimal use of dual blockade therapy for oestrogenreceptor-positive (ER+) advanced breast cancer for patients in Asia. 

Sorafenib shows favourable clinical efficacy, improved survival benefit in HCC

Audrey Abella
28 Feb 2018

The addition of the multikinase inhibitor sorafenib to FOLFOX* or transarterial chemoembolization (TACE) demonstrated favourable clinical efficacy and improved survival outcomes in hepatocellular carcinoma (HCC), according to several studies presented at the ASCO Gastrointestinal Cancers Symposium 2018 (ASCO GI 2018).

A single-arm, phase II study on 40 individuals (median age 65 years, 85 percent male) with advanced HCC revealed a median time to progression (TTP) of 8.8 months (95 percent confidence interval [CI], 6.5–11.2), an overall response rate (ORR) of 18 percent, and a stable disease rate of 55 percent after administration of twice-daily sorafenib 400 mg followed by a concurrent modified FOLFOX regimen. [ASCO GI 2018, abstract 270]

“[Sorafenib plus FOLFOX] demonstrated encouraging clinical efficacy … for first-line treatment of advanced HCC,” said the researchers, adding that the findings outdid the results of the SHARP** trial which showed a median TTP of 5.5 months and an ORR of 2 percent with sorafenib use. [N Engl J Med 2008;359:378-390]

The researchers postulated that the prolonged TTP could be attributed to the low baseline plasma levels of s-VEGF# receptor 1, VEGF-C, and bFGF##.

The randomized phase II TACTICS### trial further underscored the potential of sorafenib in prolonging median TTP when added to TACE as opposed to receiving TACE alone in unresectable HCC (24.1 vs 13.5 months, hazard ratio [HR], 0.56, 95 percent CI, 0.38–0.83; p=0.004). [ASCO GI 2018, abstract 206]

Median progression-free survival (PFS; 25.2 vs 13.5 months, HR, 0.59, 95 percent CI, 0.41–0.87; p=0.006) and time to untreatable progression (26.7 vs 20.6 months, HR, 0.57, 95 percent CI, 0.35–0.92; p=0.02) were also significantly improved with TACE plus sorafenib vs TACE alone.

A retrospective study on 232 patients with advanced HCC (mean age 71 years, 77 percent male) also demonstrated favourable results with sorafenib use, with overall survival (OS) rates of 72.4 percent, 53.6 percent, and 41.9 percent at 6, 12, and 18 months, respectively. [ASCO GI 2018, abstract 497]

“Sorafenib is the only approved first-line agent … [for] advanced HCC … Therefore, it is very important to maintain sorafenib therapy until sorafenib resistance occurs,” said the researchers of the retrospective analysis.

Given the encouraging survival and safety profile observed with regorafenib, patients who progress after sorafenib could receive regorafenib as a second-line treatment, they added. [World J Clin Oncol 2017;8:203-213]

Taken together, these findings support the favourable clinical efficacy and survival benefit associated with sorafenib, given its potential in delaying disease progression by targeting key pathways in the pathogenesis of HCC. [N Engl J Med 2008;359:378-390]

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
20 hours ago
In advanced-stage, newly diagnosed classical, CD30-positive Hodgkin lymphoma (HL), front-line therapy has resulted in durable remission rates in up to 70–90% of patients, although approximately 25–30% of advanced stage HL patients are refractory or relapse following first-line treatment with ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) chemotherapy.1–3 The standard of care for patients with relapsed or refractory (r/r) classical HL is salvage therapy using second-line high-dose chemotherapy (HDCT), followed by autologous haematopoietic stem cell transplant (ASCT) in eligible patients, which can induce a complete remission (CR) in about 50% of patients.4 Nevertheless, the prognosis of patients who relapse after the salvage HDCT/ASCT is exceedingly poor, with a median survival duration of approximately 1.2 years.5
22 Jan 2018
In a symposium chaired by Dr Yoon-Sim Yap of the National Cancer Centre Singapore, renowned regional and international experts in the field of breast cancer, Dr Yen-Shen Lu from Taiwan and Professor Nadia Harbeck from Germany, joined her in providing insights on the current treatment landscape of hormone receptor-positive (HR+) advanced breast cancer. In their respective sessions, they each highlighted new therapeutic options including the optimal use of dual blockade therapy for oestrogenreceptor-positive (ER+) advanced breast cancer for patients in Asia.